Recent discoveries about the pathogenesis and symptom structure of autism spectrum disorders (ASDs) are challenging traditional nosology and driving eff orts to reconceptualise the diagnosis of autism, a goal made all the more pressing by new prospects for early identifi cation, targeted intervention, and personalised-medicine approaches to specifi c autistic syndromes. Recognition that ASD represents the severe end of a continuous distribution of social communication abilities in the general population has stimulated attempts to standardise the measurement of autistic traits and to set appropriate clinical thresholds for diagnosis. Over the next decade, rapid advances in our understanding of symptom structure and the diversity of causes of ASD could be incorporated into the next evolution in the diagnosis of autism, with important implications for research, clinical practice, public health, and policy. As diff erential eff ects of personalised therapies are identifi ed in relation to specifi c causes of autism, the benefi ts of an updated diagnostic nosology will translate into the delivery of more eff ective care for patients.
Introduction
Until little more than a decade ago, autism was considered to be rare and usually accompanied by intellectual disability; standardised methods to calibrate the nature and severity of symptoms were not available, and only rarely could the syndrome be traced to a biological cause. All of that has changed. [1] [2] [3] Although clinician diagnosis maintains its tentative hold as the current standard for case designation, the diagnostic process is increasingly informed by scientifi c discoveries that have challenged traditional perspectives on the appropriate threshold for assigning a clinical diagnosis and on how diagnosis should relate to the specifi c cause of an autism spectrum disorder (ASD) in an individual patient. In essence, rapid advances in the science of autism have occurred in each of Robins and Guze's classic proposed requirements for the valid classifi cation of mental disorders, published in 1970 (clinical description, laboratory study, exclusion of other disorders, follow-up study, and family study). 4 The diagnostic implications of these discoveries, especially recent fi ndings related to symptom structure and biological cause, are numerous and largely encompassed by four overarching themes. The fi rst theme comprises recognised limitations of the expert clinician paradigm as a standard for diagnosis. 5 The second, the quantitative trait characteristics of ASD, refl ects evidence that the defi ning features of the syndrome are continuously (not categorically) distributed in the general population and often arise from additive genetic infl uences that are shared with other neuropsychiatric conditions. [6] [7] [8] Pronounced heterogeneity in the pathways of causation of ASD phenocopies, 9 even within families, 10 constitutes the third theme. And fi nally, the fourth theme covers pleiotropic eff ects, in which the same deleterious genetic variant can give rise to various neuropsychiatric syndromes (eg, epilepsy, schizophrenia, attention defi cit hyperactivity disorder [ADHD] , learning disability, and intellectual disability) or other non-ASD comorbidities (motor coordination defi cits or behavioural impair ments), 11, 12 depending in part on genetic background. 13 Some or all of these issues present similar challenges in the diagnosis of other complex medical disorders (eg, hypertension, diabetes, and infl ammatory bowel disease).
The aim of this Series paper is to assimilate specifi c issues that have a bearing on the diagnosis of ASD. We begin by considering the strengths and limitations of current standards for diagnosis (invoking the fi rst of the above-mentioned themes), before clarifying how the resulting diagnostic thresholds relate to the structure of symptoms in nature (the second theme). We review what is now known about the diversity of causes of autistic syndromes (the third and fourth themes), and fi nally discuss how knowledge of causation and symptom structure might be incorporated into the next evolution in the diagnostic approach to ASD. The fi fth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 14 published in 2013, represents an attempt to modify the diagnostic process in tandem with the pace of recent discovery. However, to meet the complex needs of people aff ected by ASD and other neurodevelopmental disorders, we need to continue to build upon and refi ne the existing taxonomic framework in a manner that fl exibly and faithfully accommodates advances in scientifi c understanding.
Contemporary clinical diagnosis of ASD Diagnostic criteria
We begin with the paradigm of clinician diagnosis, which is the historical bedrock of case designation. Several noteworthy scientifi c advances were recognised in the development of DSM-5, 14 which marks the fi rst major revision of the manual since the fourth edition (DSM-IV) 15 was published in 1994. The DSM-5 diagnostic criteria for ASD are presented in panel 1. We note that 1 Defi cits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation; to reduced sharing of interests, emotions, or aff ect; to failure to initiate or respond to social interactions. 2 Defi cits in non-verbal communicative behaviours used for social interaction, ranging, for example, from poorly integrated verbal and non-verbal communication; to abnormalities in eye contact and body language or defi cits in understanding and use of gestures; to a total lack of facial expressions and non-verbal communication. 3 Defi cits in developing, maintaining, and understanding relationships, ranging, for example, from diffi culties adjusting behaviour to suit various social contexts; to diffi culties in sharing imaginative play or in making friends; to absence of interest in peers.
B) Restricted, repetitive patterns of behaviour, interests, or activities, as manifested by at least two of the following, currently or by history (examples are illustrative, not exhaustive):
1 Stereotyped or repetitive motor movements, use of objects, or speech (eg, simple motor stereotypies, lining up toys or fl ipping objects, echolalia, idiosyncratic phrases). 2 Insistence on sameness, infl exible adherence to routines, or ritualised patterns of verbal or non-verbal behaviour (eg, extreme distress at small changes, diffi culties with transitions, rigid thinking patterns, greeting rituals, need to take same route or eat same food every day). 3 Highly restricted, fi xated interests that are abnormal in intensity or focus (eg, strong attachment to or preoccupation with unusual objects, excessively circumscribed or perseverative interests). 4 Hyper-or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment (eg, apparent indiff erence to pain/temperature, adverse response to specifi c sounds or textures, excessive smelling or touching of objects, visual fascination with lights or movement).
C) Symptoms must be present in the early developmental period (but may not become fully manifest until social demands exceed limited capacities, or may be masked by learned strategies in later life). D) Symptoms cause clinically signifi cant impairment in social, occupational, or other important areas of current functioning.
E) These disturbances are not better explained by intellectual disability (intellectual developmental disorder) or global developmental delay. Intellectual disability and autism spectrum disorder frequently co-occur; to make comorbid diagnoses of autism spectrum disorder and intellectual disability, social communication should be below that expected for general developmental level.
Note: Individuals with a well-established DSM-IV diagnosis of autistic disorder, Asperger's disorder, or pervasive developmental disorder not otherwise specifi ed should be given the diagnosis of autism spectrum disorder. Individuals who have marked defi cits in social communication, but whose symptoms do not otherwise meet criteria for autism spectrum disorder, should be evaluated for social (pragmatic) communication disorder. many clinical situations in which core ASD symptom burden is pronounced but impairment relatively mild, and vice versa. Consider, for example, a well-adjusted individual who was previously given a diagnosis of Asperger's disorder on the basis of very substantial ASD symptomatology, but is now successfully employed in a technical fi eld, or an individual with milder ASD-specifi c symptoms accompanied by general cognitive impairment, such that the combination results in profound impairment in adaptive functioning. Thus, symptom burden and impairment in adaptive functioning constitute orthogonal axes of diagnosis, both of which are important to measure, and it can be well argued that most of the proven benefi ts of currently available interventions for autism are in the realm of adaptive functioning, not core symptom counts. [18] [19] [20] Improvements in adaptive functioning are achievable and crucial for patients with ASD, 21 but grossly underappreciated when measuring outcomes exclusively as a function of core symptom burden, as still often occurs in clinical trials. The hybrid severity index published in DSM-5 (table) translates the eff ect of symptoms in each criterion domain (A and B) onto three broad categories of adaptive functioning, each of which is defi ned by descriptive scoring anchors that indicate the level of support that an aff ected individual requires.
The third major revision in DMS-5 is that it is now deemed appropriate to simultaneously diagnose ASD with other psychiatric or developmental disorders (eg, ADHD) when there is ample evidence for comorbidity, in view of overwhelming evidence that many known inherited causes of ASD are genetically independent from the causes of other common neuropsychiatric disorders, 22 and it is therefore entirely possible for an individual to be aff ected by more than one neuropsychiatric condition. The change will help to ensure that, regardless of causes, all the needs of an individual are recognised and addressed.
The diagnostic process
Implied, but not explicit in the diagnostic criteria themselves, are the elements of information gathering that are required to establish DSM-5 diagnostic criteria A-E (panel 1), which constitute what can be thought of as three pillars of the diagnostic process: (1) ascertainment of current symptomatology suffi cient to meet criteria A, B, and D; (2) acquisition of a developmental history consistent with an ASD (criterion C, provided by a primary caregiver of the child whenever possible); and (3) clinician confi rmation.
Since the severity of current symptomatology can vary as a function of environmental context and demands, appraisal of symptoms requires caregivers and teachers to provide accounts of an aff ected individual's behaviour in the social environment of home, school, and community: to report on their social interests and peer relationships (which cannot be ascertained on exam); to provide information on their day-to-day social communication (including use of verbal and non-verbal language and communication, imagination and play, sensory responses, self-help skills, mood, and tantrums and outbursts); and to endorse the presence or absence of the pathognomonic repetitive or stereotyped behaviours of ASD, including observations of rigid or repetitive patterns of behaviour.
Similarly, clinician confi rmation relies on a diversity of prompts to elicit a child's highest capacity for social communication, and to introduce enough sensory arousal to elicit stereotyped responses if they are not immediately evident. Depending on the age of the child What becomes immediately evident in the diagnostic process, especially for milder ASD syndromes, is that fulfi lment of DSM-5 criteria A, B, and D is, by defi nition, exquisitely sensitive to the notion of clinical threshold.
There is an apparent tension between expert clinician judgment about where these thresholds should lie and the fundamental nature of the features described by criteria A, B, and D (their respective distributions, interrelations, and biological causes) that raises continuously evolving questions about how the clinical thresholds for these criteria should be established for the purpose of diagnosis. Should they represent percentile cutoff s of the normal distribution (as dominates the diagnosis of intellectual disability)? Should a patient with an established causal mutation for ASD whose symptoms fall just below the current clinical threshold be diagnosed? Should absolute symptom burden or level of impairment of adaptive functioning dominate parameterisation of the clinical threshold? In traditional ASD research, emphasis has unequivocally been on the former. If subclinical ASD symptomatology exacerbates another primary diagnosis (eg, ADHD or borderline intellectual functioning) in a manner that substantially contributes to impairment in adaptive functioning, should a diagnosis of ASD be made?
The evolving defi nition of disorder and shifting diagnostic boundaries
Perhaps more so than for many neuropsychiatric disorders, the evolution of our conception of what autism is, and how its diagnostic boundaries should be established, has been far from linear since the initial classic descriptions over 70 years ago by Leo Kanner 25 and Hans Asperger. 26 In many ways, these pioneer clinicians got so much right. In small case-series descriptions (11 children in Kanner's description of "autistic disturbances of aff ective contact"; four children in Asperger's description of "autistic psychopathy") they described characteristic features of ASD that are instantly recognisable and still resonate with clinicians and parents today.
The diagnostic category of "infantile autism" was fi rst introduced into the psychiatric classifi cation system in the third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 27 The description, heavily infl uenced by Rutter, 28 broadly matched that of the more severe cases described by Kanner, 25 characterised by delay in language milestones and poor communication skills, intellectual disability (previously referred to as mental retardation), social aloofness, motor stereotypies, and intense, narrow, and odd preoccupations. This initial description still survives in the clinical vernacular today when clinicians refer to children as presenting with classic or Kanner autism. From this point onwards, subsequent changes to the classifi cation systems both broadened the concept of the clinical presentations that should be included in what we now call "autism spectrum disorder"-and, along with this, the number of individuals to whom the diagnosis applied-and introduced several new diagnostic labels that, in hindsight perhaps mistakenly, were taken by both the clinical and scientifi c communities to stand for meaningful subtypes Panel 2: Case study 1-autism spectrum disorder diagnosed in infancy SS, a boy whose maternal uncle had a diagnosis of idiopathic intellectual disability, was fi rst evaluated at age 15 months. His parents were concerned that he would not engage in either symbolic or pretend play. He was not capable of (protodeclarative) pointing to share intention and rarely responded to his name being called. He seemed preoccupied with things that spin and had a history of peculiar behaviours, including examining the shadows cast by his fi ngers for extended periods of time. Despite these concerns, he seemed to recognise the meaning of the word "no", would make eye contact when directly engaged, and enjoyed proximity to his parents. There was no history of head trauma or seizures and his hearing was completely intact.
On clinical examination, SS exhibited poor eye contact and was preoccupied with objects, including a ball in the room, which he began to roll forward and chase repeatedly; he did not respond to the examiner's prompts to include him in the game. He was non-verbal. His parents were counselled on methods to engage him in turn-taking reciprocal play, and they were instructed to return in 3 months to review his progress. At age 18 months he remained essentially non-verbal, exhibited stereotyped behaviours and a persistent lack of social reciprocity, and was given a clinical diagnosis of DSM-IV pervasive developmental disorder (DSM-5 autism spectrum disorder).
By age 7, after years of specialised early-childhood and early-elementary education, featuring early intensive behavioural intervention, speech and language therapy, augmentative communication, occupational therapy, and special education with an assigned 1:1 paraprofessional, his receptive language had continued to improve, although his spontaneous verbal communication remained limited to short phrases and sentences, raising concern about the presence of comorbid intellectual disability. He was fairly non-cooperative with intellectual testing and the results were not released because it was felt by the assessors that the scores underestimated his true ability. An EEG obtained because of intense visual fi xation patterns and concern for possible absence epilepsy was non-epileptiform, but abnormal in that the activity during wakefulness lacked a posterior dominant rhythm. He remained in intensive specialised education programmes, was well adapted at home with his family (entirely verbally redirectible, non-aggressive, and responsive to his parents' requests), and although content with isolation, enjoyed the company of his family and classmates at school.
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of ASD. First, the revised version of DSM-III (DSM-III-R) 29 introduced the terms "autistic disorder" and "pervasive developmental disorder not otherwise specifi ed" (PDD-NOS), the latter essentially a subthreshold defi nition for more mildly aff ected individuals. Then, in DSM-IV, 15 "Asperger's disorder" was introduced as a subcategory of the pervasive developmental disorders, recognising that individuals with average or aboveaverage intelligence and intact structural language skills could also have the clinical manifestations of ASD.
The long interval before the next revision of the manual in 2013 (DSM-5) 14 gave more time for clinical and basic scientifi c research to inform the decisions made by the Neurodevelopmental Disorders Work Group than had been allowed during the several revisions between 1980 and the mid-1990s. At least three factors were infl uential in the reversion to a single-disorder category of "autism spectrum disorder" in DSM-5.
The fi rst factor was the recognition that ASD syndromes are aetiologically as well as clinically heterogeneous, 30 as we discuss in more detail below. The second was an accumulation of research evidence that the clinical subtypes described in DSM-IV-autistic disorder, PDD-NOS, Asperger's disorder-did not have scientifi c validity in terms of distinct neurobiological or genetic aetiologies, or truly independent cognitive associates that diff ered between the diagnostic subtypes (aside from those inherent in the diff erent specifi c diagnostic criteria, in particular with regard to language and intellectual ability). 31, 32 This might be too high a bar to set for clinical diagnostic criteria, in view of the longrecognised fact that clinical utility and (natural) validity are not the same thing. 33 However, it became increasingly apparent that the diagnostic subtypes lacked clinical validity. Only a few years after the publication of DSM-IV introduced Asperger's disorder into the classifi cation system, Miller and Ozonoff 34 reviewed the original case descriptions in Asperger's 1944 paper 26 and concluded that all cases would have met DSM-IV criteria for autistic disorder. The third factor that is likely to have strongly infl uenced the DSM-5 reversion to a single ASD category was a seminal study showing that, even among expert research groups, the use of the subclassifi cations was unreliable and bore no relation to the symptom scores measured on standardised diagnostic instruments. 5 The fi nal important change in DSM-5 is the introduction of clinical specifi ers to be noted alongside the diagnosis of ASD, including the timing and nature of onset (eg, with regression) and the presence or absence of the following features: language impairment; intellectual impairment; known medical or genetic conditions; precipitating environmental factors; other specifi c neuro developmental, mental, or behavioural disorders; or catatonia. The degree to which the simplifi ed nosology and structure of DSM-5 is a better description of nature than previous conceptions of autism-and the clinical research utility of the specifi ers-will be known only when a body of empirical work using the system has accumulated.
One concern is that DSM-5 has introduced a diagnostic constriction, with epidemiological evidence suggesting that up to 20% of individuals who met criteria for one of the pervasive developmental disorders under DSM-IV do not meet DSM-5 criteria for ASD, in particular those without intellectual disability. 35, 36 DSM-5 has also introduced a new diagnostic category termed "social (pragmatic) communication disorder", characterised by persistent diffi culties in the use of verbal and non-verbal communication for social purposes, in the absence of restricted and repetitive interests and behaviours, although its clinical utility and relation to ASD are currently unknown. 37 It remains to be seen how health services, insurers, and commissioners will respond to these radical changes to the diagnostic system, and also whether family members and individuals with ASD will Panel 3: Case study 2-autism spectrum disorder diagnosed in childhood DP was an 8-year-old boy when he was fi rst brought to the attention of clinicians. He was described by his mother as being "diff erent" from a very young age. He had an unusual interest in books about geology and was exceptionally good at puzzles. He was inclined to repeat dialogues he had heard on television and passages from books to get ideas across. He had poor motor skills and at times endangered himself by mindlessly walking onto busy streets.
During his preschool years, DP had rarely socialised with other children and seemed more disinterested than anxious when in their company. In elementary school, he was one of the fi rst children in his class to read independently and was very profi cient in mathematics, but he was stigmatised by his behaviour. He answered his teachers' rhetorical questions aloud, without being called upon to do so, and blurted out inappropriate comments to peers, which he often found humorous. His parents and teachers reported that he was disliked by his classmates, regarded as odd by them, and often teased, although he seemed largely oblivious to this.
On clinical examination, he showed considerable diffi culty in maintaining the fl ow of a conversation with the examiner, talking around the subject rather than providing direct responses, and repeatedly resorted to changing the topic of conversation to discuss diff erent types of rocks and geological formations. His eye contact was reasonably good when directly engaged in conversation, but he otherwise appeared aloof and somewhat detached. He spoke in a monotone voice, largely devoid of prosodic intonation. He had little insight into the way in which he was negatively regarded by his classmates and referred to them as his "friends" despite his mother's assertion that they never asked to play with him or included him in after-school gatherings.
A structured diagnostic interview about his developmental history revealed a level of symptoms that fell just below the threshold for meeting diagnostic criteria for an autism spectrum disorder; however, the burden of symptoms and level of impairment evident from the accounts of his parents and teachers, which were confi rmed by clinical observation and deemed unlikely to be attributable to an alternative psychiatric diagnosis (eg, ADHD, intellectual disability, anxiety disorder, or language disorder) resulted in a clinical diagnosis of autism spectrum disorder (DSM-5).
DP was enrolled in group-based social-skills training, which gradually helped to resolve his more stigmatising social behaviours, and he received psychiatric care for an interval during adolescence when he became depressed. He is now enrolled in his third year of undergraduate studies at a college that provides social support to students on the autism spectrum.
Series welcome the changes. We also note that there are as yet unresolved questions about whether diagnoses such as social communication disorder (in which social communication defi cits and restricted, repetitive behaviours are dissociated) and Asperger's disorder (eliminated from DSM-5; in which social communication and structural language impairments were dissociated) represent biologically tractable subtypes of ASD, 38 irrespective of whether they fall into phenotypic or genetic continua with the remainder of the spectrum.
Finally, and at fi rst sight somewhat contradictorily, alongside the recognition that there is wide heterogeneity and variability in the presentation of autism-across individuals who meet diagnostic criteria for ASD, among their close relatives, and to some degree within individuals over the life course-there was a recognition in the development of DSM-5 that the core features can be better understood as a spectrum of presentations. The seminal work of Wing 39 and Nordin and Gillberg 40 in recognising this spectrum, and of Pickles and colleagues 41 and Piven and colleagues 42 in introducing the notion of a "broader autism phenotype", stimulated attempts to standardise the ascertainment of autistic symptoms for both aff ected and unaff ected individuals in families with ASD.
DSM-5 has clarifi ed the symptom criteria for ASD, operationalised the distinction between symptom burden and impairment, and alluded to the continuous nature of autistic traits in the general population. Nevertheless, the questions of where to draw the diagnostic line and how to incorporate the assignment of specifi c genetic causes to an increasing proportion of all cases of ASD present important challenges and opportunities in the diagnosis of autism. Our responses to these questions will have direct implications for those aff ected in terms of access to support services and personalised approaches to medical care.
Progress in the measurement of autistic traits Standardised measures of symptom burden
A range of screening and diagnostic instruments for ASD has been developed over the past two decades. 23 However, a long list of potential methods to choose from is not necessarily a good thing for either the clinical or the research fi eld, particularly in view of the fact that the properties of many of these instruments have not been extensively studied or well established. However, several instruments have been widely validated and are increasingly used in research and clinical practice in many countries. They range from checklist questionnaires for screening and rapid ascertainment of symptom severity to structured diagnostic instruments, including the Autism Diagnostic Interview, Revised (ADI-R), 43 the Developmental, Dimensional and Diagnostic Interview (3di), 44 and observational measures such as the Autism Diagnostic Observation Schedule, second edition (ADOS-2). 45 Although there is, as expected, overlap in the concepts and the content of ASD rating scales and diagnostic instruments, they diff er in the aspect of the diagnostic process to which they apply (ie, developmental history vs current symptom ascertainment vs clinician confi rmation), the populations for whom they are standardised, and the degree to which they are sensitive measures of subclinical variation in ASD traits. They also vary in terms of the need for trained raters, the time needed to train raters or to complete assessments, and the cost and feasibility of application in clinical settings. Among the most notable limitations is the degree to which the accuracy of many screening and diagnostic instruments has been validated in individuals with ASD with intellectual disability. There is also recognition that few of the methods have been validated in non-western cultures or in low-income or middle-income countriesin part, the same could be said about the diagnostic construct, an issue that Lotter studied in the 1970s 46 although such work has begun. 47 
Quantitative approaches to the measurement of autistic traits
When standardised methods for quantitative assessment of ASD symptoms and traits have been applied to the general population, the unequivocal fi nding from a host of studies, implementing numerous methods of measurement, is that the traits and features that characterise autism are continuously-not bimodallydistributed in nature. 6, 8, 44, 48 This observation implies that there is an arbitrary nature to diagnostic cutoff s in ASD, and points to the need for methods of the type that have been applied to other quantitative human traits-such as height, weight, intelligence, and blood pressure-to derive standardised, percentile-based guidelines for clinical diagnosis. Remarkably, the characteristic traits and symptoms of the autistic syndrome (defi cits in reciprocal social behaviour, impairment in social communication, repetitive behaviour, and restriction in range of interests) are as highly inter-related in the general population as they are (by defi nition) in individuals with clinical ASD syndromes. Such homologous factor structures substantiate the use of unitary scores (akin to IQ for intelligence) as valid indices of symptom burden in both clinical and non-clinical populations, 49 even though the overlap in biological causation of the respective symptom domains is not fully understood. 50 At present, whether subprofi les of the autistic syndrome-featuring, more or less, involvement of one or another of the respective symptom domains-will reliably map to independent sets of biological causes remains unclear. 51 Furthermore, when standardised quantitative methods are implemented in the study of families aff ected by ASD, subclinical autistic symptoms and traits are observed among fi rst-degree relatives with a frequency an order of magnitude higher than that observed in the general population. 52, 53 Recently, in very Series large genetic-epidemiological studies, it has been confi rmed that the genetic susceptibilities to these subclinical syndromes exhibit near-complete overlap with genetic underpinnings of the clinical-level syndromes, 54 strongly suggesting that the continuous distributions observed in nature relate to quantitative accumulation of causal susceptibility. A more detailed review of discrete subpopulations that partly contribute to the continuum observed in nature has been published previously. 6 Thus, although the diagnostic criteria for ASD do not yet consider percentile rank in the population distribution (as do diagnostic criteria for anorexia nervosa, hypertension, intellectual disability, and short stature), an increasingly compelling case can be made for parameterising diagnostic thresholds in this manner. 55 An in-depth, two-stage population study of autism prevalence indicated that 2·5% of the population are aff ected, 56 approaching the proportion that defi nes clinical thresholds for other human quantitative traits (eg, height and short stature). A recent systematic review of studies of members of the general population that used the Autism Spectrum Quotient (AQ), a self-report measure of autistic traits, showed that both males and females have a close-to-normal distribution of traits but that there is a highly signifi cant shift in distribution between the sexes, with males scoring higher than females. 57 Failure to incorporate sex-specifi c norms in the diagnostic process has contributed to signifi cant diff erences in the rates of community diagnosis for girls versus boys who manifest precisely the same level of quantitative symptom burden, 6, 58, 59 and there is evidence that female sex can very often moderate the phenotypic expression of inherited susceptibility to ASD. 60, 61 Moreover, in the same way that height infl uences weight, the neurodevelopmental characteristics of intelligence, attention, structural language capacity, emotion regulation, and executive function can infl uence social communication, such that specifi cation of the role of autistic symptomatology in an individual patient will ultimately require established maps of the predictable relations between the variables (analogous to the heightvs-weight norms for males and females used in paediatric practice) to accurately ascertain the relative contribution of ASD symptomatology to a given neurodevelopmental syndrome. 62 This is becoming especially relevant as we understand more fully the biological infl uences on each (separable) axis of human development, and we recognise that even rare monogenic syndromes commonly have adverse eff ects on multiple domains of development (eg, eff ects of 16p11.2 rearrangements on intelligence, social responsiveness, and weight 13 ), each infl uenced by the mutation in a manner that represents a predictable shift against a (bi-parental) genetic and environmental background for that trait. In this way, rare syndromes can be more deeply understood, not simply by the variable and idiosyncratic array of defi cits with which they are associated, but by how they infl uence such traits in the setting of the specifi c genetic and environmental background of an individual.
Causation and an impending revolution in ASD diagnosis
The past decade has witnessed an explosion in scientifi c discovery of the causes of autism. Although, so far, neither a laboratory test nor a neural signature that can reliably establish the presence of a non-syndromic ASD is available, a rapidly increasing proportion of all casesapproaching the majority-can be attributed to the infl uence of deleterious genetic variants or combinations of variants, and it is expected that understanding of the genetics of autism will play a major part in revolutionising diagnosis. Twin and family studies involving tens of thousands of individuals in ASD-aff ected families have overwhelmingly established the predominant role of genetic factors in the causation of most autistic syndromes. [63] [64] [65] Accumulated results of genetic studies have led to enormous progress in accounting for the inherited variance associated with autism. The fi rst important fi nding of such studies has been that of causal heterogeneity: a diverse array of rare (less than 1% of all cases, usually less than 0·1% of all cases), highly penetrant mutations-some de novo, some recessively inherited, most involving autosomal loci-contribute to ASD susceptibility in up to 40% of autistic syndromes. 9, 66 Second, these studies have revealed pleiotropic eff ects of rare causal variants: many of the rare variants that have been repeatedly associated with ASD have also been strongly implicated in the causation of other neuropsychiatric syndromes, including epilepsy, ADHD, schizophrenia, and intellectual disability. 11 Furthermore, in the presence of some highly penetrant disease-causing mutations (eg, 16p11.2 deletion syndrome), the expression of ASD symptoms-ascertained using standardised methods-can be highly variable, infl uenced in large measure by family genetic background. 13 The third important research fi nding relates to quantitative genetic risk: common allelic variations, each presumably individually preserved in the human population on the basis of adaptive value (in an evolutionary sense)-and none of which singly can account for more than a tiny elevation in the risk for ASD (odds ratio between 1·0 and 1·2)-are responsible for most of the genetic risk for ASD on the basis of cumulative polygenic risk. 7 Finally, specifi c sets of common and rare inherited allelic variations have been associated with a range of neuropsychiatric conditions (including both childhood-onset and adultonset disorders), and further resolution of these genotype-phenotype relations will contribute to a shift beyond descriptive syndromes towards a nosology informed by causation. 11, 66, 67 These fi ndings have collectively suggested that the continuum of ASD traits observed in the population refl ects the human distribution of polygenic risk, Series superimposed by clusters of cases attributable to a massively overlapping array of rare, discrete genetic variants with a moderate-to-high level of penetrance. In turn, the phenotypic expression of these genetic infl uences varies on the basis of the manner in which they interact with other key attributes of the individual, including genetic background, 13 sex, 59-61 the intrauterine environment, and early life experience 55 (including, for example, infectious diseases, serious medical complications during the neonatal period, or as yet poorly understood eff ects of variation in the human microbiome). These interactions between various causative factors reinforce the need for a personalised-medicine approach to both diagnosis and treatment, as is now implemented for many complex diseases, most notably in the fi eld of oncology.
Resolution of many autistic syndromes with respect to the relative contribution of specifi c genetic variants also continues to illuminate understanding of the biology of autism comorbidities, such as ADHD, motor coordination impairment, [68] [69] [70] epilepsy, intellectual disability, anxiety, and the psychopathologies. Although none of these symptom clusters is specifi c to ASD, some mutations-eg, those associated with fragile X syndrome (FMR1), neurofi bromatosis type 1 (NF1), tuberous sclerosis, and a host of newly discovered variants-have been associated with predictable profi les of comorbidity (whenever ASD arises) and therefore blur the distinction between core symptoms and associated symptoms, at least in the setting of these monogenic syndromes. 71 In other pathways to ASD, associated symptoms are better predicted by family genetic background, seem to be exacerbated by the presence of ASD, and are not themselves predictive of a specifi c ASD susceptibility. 51 In summary, advances in understanding the causes of autism-its genetic and population structure-suggest that diagnosis will ultimately benefi t from further movement towards standardised quantitative characterisation of the defi ning features of ASD, conducted simultaneously with (and controlling for) multi-axial characterisation of those aspects of human development that infl uence the manifestation of autistic symptoms and impairments, and from the inclusion of genotype in taxonomic classifi cation. For some putative causes of ASD, we are still at an early stage in the conversion from statistical association in large genetic studies to knowledge of the specifi c impact of a deleterious variant in an individual patient. Recently, Yuen and colleagues 10 showed that among siblings concordantly aff ected by ASD, when one carries what would be presumed to be a highly deleterious variant, the other aff ected sibling may not share that variant, such that familial susceptibility is driven more by background genetic factors upon which rare variants not shared between family members are responsible for crossing over the tipping point of clinical-level eff ect.
As the cost of genotyping continues to fall, as false discovery rates are minimised, 72 as an increasing proportion of patients' conditions are traced to specifi c genetic variants, and as the sample sizes of large genetic registries continue to grow, specifi cation of the relative eff ect of causal and protective variants in individuals will increasingly become feasible. Even as this fi eld is evolving, the calibration of clinical practice in a manner that raises awareness among clinicians of the eff ect and relevance of quantitative phenotypes, of multiplier eff ects of comorbid developmental liabilities, and of the opportunity to subgroup patients on the basis of deleterious variants, stands to accelerate the discovery process. As diff erential eff ects of personalised therapies are identifi ed in relation to specifi c genetic origins, [73] [74] [75] the benefi ts of an updated diagnostic nosology-including positive eff ects on the pace of new discovery-will translate into the delivery of more tailored and sophisticated care for patients.
Advancing the frontier of early diagnosis
Another traditional diagnostic boundary that is being challenged by advances in science is the timing of diagnosis. It has long been recognised that ASDs have an early onset, and a primary motivation for seeking to lower the age of diagnosis of ASD is to enable evidence-based interventions to be put in place. 76, 77 Several converging lines of evidence support the view that early intervention can lead to more positive outcomes: the presence of higher neural plasticity early in life; 77 evidence from prospective infant sibling studies that atypical neurodevelopment might be present even in the fi rst year of life in those who subsequently develop symptoms of ASD; 78 and preliminary evidence that some of these atypical developmental processes might be amenable to intervention from as young as 10 months of age. 79, 80 Over the past 20 years, an increasing number of studies has reported on outcomes of children with ASD diagnosed at a very young age, either from clinical referrals of young children or from children identifi ed as at risk on the basis of screening or familial risk. After initial studies by Lord 81 and Cox and colleagues, 82 more recent studies have followed children from 2 years to 7 years 83 and 9 years 84,85 of age. In short, these studies show that diagnosis from as young as 2 years of age 86 is relatively stable and that the judgment of experienced clinicians is more reliable than that of existing diagnostic instruments for this age group. Notwithstanding the evidence in support of clinical judgment, there can be particular diffi culties when considering a diagnosis of ASD in very young children, ranging from overlap in presentation (and hence diff erential diagnosis) in the case of children with intellectual disability or language delay, to the diffi culty in judging the extent to which there is an impairment in adaptive and wider social functioning (eg, when a young child is mostly cared for by parents or familiar caregivers and has little opportunity for broader social interaction with peers). In such circumstances, the notion of a working diagnosis with Series ongoing surveillance, monitoring, and review over the course of sequential assessments can be valuable and help both clinicians and parents to better understand and recognise the pattern of development that will clarify the diagnosis one way or the other. 87 Increasingly sophisticated approaches have been adopted to examine trajectories of ASD symptoms over time. These studies have shown that, in most individuals, symptom profi les are relatively stable from age 2 years to adolescence, although about 20% of children who are ultimately diagnosed with ASD have marked regressions after apparently healthy developmental progress over the fi rst 2 years of life. Moreover, around 10% of individuals show improving trajectories, 17 dubbed "bloomers" by Fountain and colleagues. 88 Confi rming the broad independence between symptom severity and adaptive impairment, a recent study has shown that distinct trajectories groupings defi ned by these domains are largely non-overlapping during the preschool period. 89 Similar analyses have been conducted with infants at familial risk of ASD on the basis of having an older sibling with a diagnosis. Using this at-risk design, it is possible to track from as young as 6 months of age the trajectory of the roughly 20% of at-risk siblings who go on to have ASD at 36 months of age. 90 Landa and colleagues 91, 92 and Ozonoff and colleagues 93, 94 have shown that although the diff erent outcome groups look similar at 6 months of age, soon afterwards the trajectories of those who go on to receive a diagnosis of ASD begin to diverge, with subtle developmental slowing across a range of domains, including motor, language, and social communication abilities (fi gure).
The task ahead is to understand the constitutional (eg, variability in genetics and brain structure and function) and environmental (eg, demographics and specifi c interventions) factors that infl uence such trajectories. Until recently, the evidence base for psychological interventions with young children with ASD was poor in terms of both quality and quantity. However, a new wave of well-designed randomised controlled trials is providing increasing support for interventions that use behavioural and developmental approaches. 18, 95, 96 For example, Dawson and colleagues 95 reported improvements in language and communication skills in preschool children with ASD after 2 years of intensive developmental behavioural therapy (the Early Start Denver Model) delivered by trained specialists and caregivers. And Kasari and colleagues 96 reported that dyadic joint engagement in preschool children with ASD improved after 3 months of twice-weekly caregiver-mediated intervention.
Eff orts to advance earlier diagnosis have also revealed neurocognitive signatures of early ASD risk that might yield a fi rst generation of diagnostic biomarkers that are shared by many or most autistic syndromes. Studies of infants at familial risk of ASD have used novel technologies-including eye tracking and EEG or event-related potential methods-to study infant neurocognitive predictors of later ASD diagnosis. 78 Several neurocognitive biomarkers have been identifi ed in the fi rst year of life. These include diff erences in social response, such as a decline in eye fi xation when viewing faces between 2 and 6 months, 97 reduced social orienting, 98 and a reduced neural response to dynamic gaze shifts from 6 months of age. 99 However, diff erences in non-social neurocognitive processes have also been associated with later ASD, including shorter fi xation duration at 7 months of age 100 and a decline in attentional disengagement ability between 7 and 14 months. 101 Although no integrative theoretical account has achieved widespread acceptance, several models of emergent neurodevelopmental atypicality have been proposed. 102, 103 The clinical fi eld awaits the outcome of translational work (which has now begun) before such technologies can be used in a reliable way to augment behavioural assessment of individual infants and toddlers to aid early diagnosis in the future. However, whether the fi ndings from studies of infants with high familial risk will generalise to the broader population of individuals with ASD remains unclear, as does the extent to which the fi ndings are specifi c to ASD as opposed to other neurodevelopmental disorders (eg, ADHD and language delay), and caution is therefore required. 104 Even when reliable diagnostic biomarkers are ready for implementation, it will be important for clinicians to remain mindful of the limitations of prediction in The trajectories are based on a prospective study 93 of 25 infants later diagnosed with an autism spectrum disorder (ASD) and 25 sex-matched children at low risk of ASD who were later determined to have typical development (TD). Participants were evaluated at 6, 12, 18, 24, and 36 months of age. Frequencies of gaze to faces, social smiles, and directed vocalisations were coded from video. Examiners rated three behaviours-frequency of eye contact, frequency of shared aff ect, and overall social responsiveness-to create a social engagement composite score (range 3-9). The results suggest that behavioural signs of autism are not necessarily present as early as 6 months of age, but begin to emerge in the fi rst year and early in the second year of life. Reproduced from Ozonoff and colleagues, 93 by permission of Elsevier. 
Factors associated with under-diagnosis
Over the past decade, it has become clear that several social and cultural factors are associated with the likelihood of receiving a community clinical diagnosis of ASD. 105 Even when showing the same level of ASD symptoms, girls are less likely to be diagnosed than are boys, and those who do receive a diagnosis have more intellectual and behavioural impairment than do boys with a diagnosis. 58 The extent to which this disparity can be attributed to the thresholds on current screening and diagnostic instruments (or clinical judgment) working diff erently for males and females (and thus needing sexspecifi c recalibration) remains unclear, as does the question of whether girls are typically protected against the expression of inherited ASD susceptibility in a manner that contributes to the universally observed male-to-female ratio of 3·5:1 among those with a diagnosis of ASD. 52, 59, 60, 106 Whatever specifi c genetic, developmental, or environmental factors play a part in this sex diff erence in prevalence, it is clear that they are operating between the time of conception and the end of the second year of life, when most ASD diagnoses are manifest and the higher prevalence in boys is fully apparent. A distinct public-health consequence of nonrecognition of autistic syndromes in females relates to the risk of transmission of ASD to their own off spring. 53, 60 Except for families transmitting known deleterious variants, very little is known about how to estimate intergenerational transmission risk for women aff ected by undiagnosed (subclinical) autistic syndromes that run in their families and are expressed more prominently, phenotypically, in male relatives. Another factor that leads to under-diagnosis is social disadvantage (parental education, income, and socioeconomic status) and minority ethnic status. [107] [108] [109] Clinicians need to be alert to the possibility of under-identifi cation and take special care as part of the diagnostic assessment process to consider the needs of potentially disadvantaged groups.
Among populations of children whose parents and caregivers are unaware of the early symptom manifestations of autism, or who do not have access to primary paediatric care, or whose primary-care providers are inexperienced in screening for the characteristic symptoms of ASD, diagnosis can be delayed and early opportunities for intervention lost. The prevalence of community diagnosis of ASD varies worldwide and data are missing for many developing regions, where children and young people with ASD often go undiagnosed. 110 Resources and capacity building are urgently needed in low-income and middle-income countries to increase awareness of ASD among health-care professionals and the public.
Conclusions and future directions
Key considerations for a reconceptualisation of diagnosis in autism, informed by the scientifi c advances described above, are summarised in panel 4. At times, the process of translation of scientifi c fi ndings into clinical practice can feel frustratingly slow to clinicians and patients alike. However, the pace of discovery that
Panel 4: Reconceptualising the diagnosis of autism spectrum disorder
The next generation of advances in the classifi cation of autism spectrum disorder (ASD), based on rapid advances in the science of autism and better understanding of other neuropsychiatric and neurodevelopmental conditions, could be associated with several improvements in the diagnosis of ASD, with implications for research, clinical practice, public health, and policy. Key refi nements that we hope to see are listed below.
• A refi ned diagnosis should refl ect the fact that ASD represents the severe end of a continuous distribution of social communication abilities in the general population.
• Symptom ascertainment should be standardised for sex and mental age.
• The interactions and expected relations between autistic symptomatology and other (quantitative) infl uences on child development should be specifi ed (as expectations for weight are based on height and standardised in the concept of body mass index).
• The infl uences of subclinical autistic symptoms and other dimensions of socialbehaviour liability that jointly result in clinical-level impairment in adaptive functioning should be subsumed into a coherent nosology without necessarily invoking the double diagnosis of comorbidity.
• When identifi ed, specifi c causal infl uences (eg, monogenic syndromes), their unique profi les of behavioural disability and symptom burden, their associated symptoms (eg, epilepsy, intellectual disability, attention defi cit hyperactivity disorder), and their interactions with background (polygenic) inherited susceptibilities should be recognised in the diagnostic system. • Pleiotropic eff ects of known causes of ASD should be categorised in a manner that recognises their potential to infl uence other psychiatric syndromes.
• Motor coordination impairment should be incorporated into sets of criteria that are suffi cient to make the diagnosis. • Protocols and algorithms for feasible ascertainment of developmental history, current symptom burden, and clinical confi rmation should place reliable, expedient diagnosis within reach for most children in public health-care settings.
• Impairments in adaptive functioning attributable to the characteristic symptoms of ASD should be more precisely specifi ed, standardised, and implemented as standards for eligibility for access to services.
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has shaped our understanding of what autism is has been very rapid over the past decade. When combined, accumulating information about what causes ASD in any individual, and how this relates to the variability in family risk and transmission, and increasing understanding of how the clinical syndrome and its causes relate to variation in ASD traits within the broader population, put us at a tipping point in terms of the approach to diagnosis. Rapid advances in our understanding of the quantitative nature of autistic traits, the heterogeneity of genetic factors that contribute to ASD susceptibility, and the phenomenon of pleiotropy-coupled with increasingly evident limitations of the clinician diagnosis-are moving the specialty beyond the traditional model to one that is increasingly guided by biological measurement. Progress in many areas of study, including developmental biology, genetics, 65 epidemiology, and neuroimaging 112 will ultimately help to hone the diagnostic process and assist in the identifi cation of subsets of ASD patients who are likely to benefi t from specifi c therapies, including existing therapeutic options and treatment approaches that have yet to be discovered. In turn, once subtypes of ASD (based on aetiology or response to treatment) are known and validated, future epidemiological studies will need to describe prevalence and incidence rates at both the subtype and the global diagnostic level to allow more tailored service planning and to monitor and understand possible changes in prevalence over time. While some viewed the revisions to the classifi cation of ASD in DSM-5 as something of a revolution-and notwithstanding the perspective that many of the changes we have discussed should lead to better clinical practice, benefi ting patients and their families-translational discoveries over the next decade might make DSM-6 a very interesting read and hail a true revolution in scientifi cally informed clinical practice.
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Search strategy and selection criteria
We searched PubMed for papers published between Jan 1, 2000, and Jan 31, 2015, using the search terms "autism", "diagnosis", "family studies", and "genetics". We also searched our own fi les and the reference lists of selected papers. We selected only papers published in English. The fi nal reference list was generated on the basis of relevance to the topics covered in this Series paper, the aim of which is to synthesise recent scientifi c advances that have a direct bearing on the challenges of and potential refi nements to the diagnosis in autism.
